Last 35.00 GBp
Change Today -0.25 / -0.71%
Volume 159.3K
As of 11:30 AM 03/2/15 All times are local (Market data is delayed by at least 15 minutes).

futura medical plc (FUM) Snapshot

Open
35.25 GBp
Previous Close
35.25 GBp
Day High
35.25 GBp
Day Low
35.00 GBp
52 Week High
05/2/14 - 68.75 GBp
52 Week Low
01/21/15 - 26.25 GBp
Market Cap
34.7M
Average Volume 10 Days
218.8K
EPS TTM
-0.04 GBp
Shares Outstanding
99.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for FUTURA MEDICAL PLC (FUM)

Related News

No related news articles were found.

futura medical plc (FUM) Related Businessweek News

No Related Businessweek News Found

futura medical plc (FUM) Details

Futura Medical plc engages in the research and development of pharmaceutical drugs and medical devices in the United Kingdom. The company offers CSD500, a condom that incorporates an erectogenic compound to help men maintain a firmer erection during intercourse whilst wearing a condom; MED2002, a gel applied directly to the penis for the treatment of male erectile dysfunction; and PET500, a topical spray that enables men to prolong their sexual experience. Its pain relief management products, such as TPR100 and TIB200 incorporates a non-steroidal anti-inflammatory drug; and SPR300 a topical gel combines methyl salicylate and menthol. The company was incorporated in 2001 and is headquartered in Guildford, the United Kingdom.

6 Employees
Last Reported Date: 03/28/14
Founded in 2001

futura medical plc (FUM) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: 199.8K GBP
Finance Director, Secretary, Financial Contro...
Total Annual Compensation: 129.7K GBP
Chief Scientific Officer and Adviser to the B...
Total Annual Compensation: --
Compensation as of Fiscal Year 2013.

futura medical plc (FUM) Key Developments

Futura Medical plc Announces Appointment of CRO for MED2002 Clinical Study

Futura Medical plc announced that it has appointed a clinical research organisation (CRO) to conduct its forthcoming clinical efficacy study on MED2002, the Company's topical gel for the treatment of erectile dysfunction (ED). The study, which will take place in the UK, is expected to commence in first quarter of 2015 and report in fourth quarter of 2015. The CRO for this study is the same CRO that conducted the successful pivotal study for CSD500, the Company's novel condom which launched several months ago and shares the same active ingredient as MED2002. In contrast to CSD500, MED2002 is expected initially to be a prescription-only product. Approximately 140 patients with ED will participate in the study, which will be a randomised, placebo-controlled, double blind, home use, cross-over design. The primary outcome of the study is statistically significant efficacy.

David Davies to Leave as Director of Futura Medical plc

Futura Medical plc announced that David Davies has decided to leave the company to pursue new opportunities. Mr. Davies' departure from the company will take place during the first half of next year after the transition of his responsibilities to Futura's recently strengthened product development team.  The effective date of his ceasing to be a Director of the company will be confirmed in due course.

Futura Medical plc Signs an Exclusive Licensing Agreement with Kwang Dong Pharmaceutical Co Ltd

Futura Medical plc announced that it has signed an exclusive licensing agreement with Kwang Dong Pharmaceutical Co Ltd. (Kwang Dong Pharmaceutical) for the marketing and distribution of CSD500, Futura's novel condom, in South Korea. Under the terms of the agreement, Kwang Dong Pharmaceutical will hold exclusive rights to market and distribute CSD500 in South Korea. Financial details are not being disclosed although Futura will receive an upfront payment and royalties on all product sales along with certain minimum performance guarantees.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
FUM:LN 35.00 GBp -0.25

FUM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for FUM.
View Industry Companies
 

Industry Analysis

FUM

Industry Average

Valuation FUM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 481.9x
Price/Book 2.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 596.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact FUTURA MEDICAL PLC, please visit www.futuramedical.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.